<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300885</url>
  </required_header>
  <id_info>
    <org_study_id>11961</org_study_id>
    <secondary_id>2005-005245-19</secondary_id>
    <nct_id>NCT00300885</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel
      plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on the results of the interim analysis, it was determined that the study would not meet
    its primary efficacy endpoint and the study was terminated early.
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo</measure>
    <time_frame>Outcome measure was assessed every 3 weeks starting from randomization, during treatment period and every 3 months during follow-up period until death was recorded or up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
    <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
    <description>PFS determined as time (days) from the date of randomization at start of study to disease progression (radiological or clinical) or death due to any cause, if death occurs before progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Best Response</measure>
    <time_frame>Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
    <description>Best overall tumor response for the ITT population was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
    <description>Duration of response (PR or better) is defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome as Assessed by FACT-L Score. Change From Baseline in Total FACT-L at Cycles 3,5,7,9 and End of Treatment (EOT)</measure>
    <time_frame>Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every other cycle (i.e. Cycle 3, 5, 7 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis</time_frame>
    <description>Functional Assessment of Cancer Therapy - Lung cancer subscore (FACT-L). Patient reported outcome as assessed by FACT-L score. FACT-L questionnaire comprises statements about physical, social / family, emotional and functional well-being as well as additional concerns which have to be rated by the patients (0=&quot;not at all&quot; to 4=&quot;very much&quot;). Cycle duration defined as 21 days. Change from baseline in Total FACT-L on day 1 of cycles 3,5,7,9 (weeks 7,13,19 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome as Assessed by LCS Subscale Score. Change From Baseline in LCS Subscale at Cycles 2 Through 9 and at End of Treatment (EOT)</measure>
    <time_frame>Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every cycle (i.e. Cycle 2, 3, 4, 5 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis</time_frame>
    <description>Lung Cancer Symptoms (LCS) subscale ranges from 0 (severe debilitation) to 28 (asymptomatic). Cycle duration defined as 21 days. Change from baseline in LCS Subscale on day 1 of cycles 2 through 9 (weeks 4,7,10,13,16,19,22 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">926</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Sorafenib + C/P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + C/P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel</intervention_name>
    <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
    <arm_group_label>Sorafenib + C/P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin plus Paclitaxel</intervention_name>
    <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
    <arm_group_label>Placebo + C/P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IIIB (with effusion) or Stage IV NSCLC any histology

          -  No prior chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Greater than or equal to 18 years of age

          -  Life expectancy at least 12 weeks

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Prior systemic anti cancer therapy

          -  Known brain metastasis. Patients with neurological symptoms should undergo at computed
             tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain
             metastasis

          -  Pulmonary hemorrhage/bleeding event &gt; Common Terminology Criteria for Adverse Events
             (CTCAE) Grade 2 within 4 weeks of first dose of study drug

          -  Thrombotic or embolic events including Transient ischemic attack (TIA) within the past
             6 months

          -  Uncontrolled hypertension

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Major surgery within 4 weeks

          -  Evidence or history of bleeding diathesis or coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211-1850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92829</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Highland</city>
        <state>California</state>
        <zip>92346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kokomo</city>
        <state>Indiana</state>
        <zip>46902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <zip>67502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dover</city>
        <state>Ohio</state>
        <zip>44622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pottsville</city>
        <state>Pennsylvania</state>
        <zip>17901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trophy Club</city>
        <state>Texas</state>
        <zip>76262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richlands</city>
        <state>Virginia</state>
        <zip>24641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Palomar - Morón</city>
        <state>Buenos Aires</state>
        <zip>1684</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AVG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7602CBM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1405DCS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal-Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fé</city>
        <zip>S3000FFV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Macquarie</city>
        <state>New South Wales</state>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40050410</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60336-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60430-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>70390907</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74605-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nova Lima</city>
        <state>Minas Gerais</state>
        <zip>34000000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80730-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90619900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <zip>89202-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaú</city>
        <state>Sao Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14015-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <state>Sao Paulo</state>
        <zip>09090-780</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocaba</city>
        <state>Sao Paulo</state>
        <zip>18030-510</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01331010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <zip>30380490</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7L 2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6W 3X4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>760 0448</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>836-0156</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>838-0455</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny Cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen</city>
        <zip>14073</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06102</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hofheim</city>
        <state>Hessen</state>
        <zip>65719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hemer</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leverkusen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Großhansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <zip>5703</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matrahaza</city>
        <zip>3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torokbalint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwolle</city>
        <zip>8011 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>53-439</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117837</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zamora</city>
        <zip>49021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gävle</city>
        <zip>801 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bornemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for information of Bayer products for Europe</description>
  </link>
  <results_reference>
    <citation>Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Apr 10;28(11):1835-42. doi: 10.1200/JCO.2009.26.1321. Epub 2010 Mar 8.</citation>
    <PMID>20212250</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2006</study_first_submitted>
  <study_first_submitted_qc>March 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2006</study_first_posted>
  <results_first_submitted>November 4, 2009</results_first_submitted>
  <results_first_submitted_qc>August 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2010</results_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 150 centers across 20 countries, which enrolled and randomized at least one subject. From a total of 1043 subjects who were screened, 926 subjects were randomized between 15 February 2006 and 9 May 2007 in 20 countries.</recruitment_details>
      <pre_assignment_details>Of the 926 subjects who were randomized, 922 received at least one dose of study drug. All 926 subjects were included in the ITT population (intent-to-treat; defined as all randomized patients), all but four subjects did receive study drug. They were not included in the safety population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib + C/P</title>
          <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + C/P</title>
          <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="464"/>
                <participants group_id="P2" count="462">ongoing in double -blind treatment at data cut-off</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="463"/>
                <participants group_id="P2" count="459"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
                <participants group_id="P2" count="374"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="238"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Random code broken (subject died)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with study medication</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="354">Subjects entered Follow-up period after termination of Treatment period due to any reason.</participants>
                <participants group_id="P2" count="369">Subjects entered Follow-up period after termination of Treatment period due to any reason.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176">Subjects still in Follow up period at data cut-off date.</participants>
                <participants group_id="P2" count="174">Subjects still in Follow up period at data cut-off date.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib + C/P</title>
          <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + C/P</title>
          <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="464"/>
            <count group_id="B2" value="462"/>
            <count group_id="B3" value="926"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="34" upper_limit="86"/>
                    <measurement group_id="B2" value="63" lower_limit="34" upper_limit="82"/>
                    <measurement group_id="B3" value="62" lower_limit="34" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG (Eastern Cooperative Oncology Group) Performance Status</title>
          <description>ECOG 0 versus 1 was a stratification factor for randomization. ECOG Performance Status is a rating of daily living abilities, from 0 to 5: 0= fully active without restriction. 1= restricted in physically strenuous activity; 2= ambulatory, capable of all selfcare; 3= capable of limited selfcare; 4= completely disabled; 5= dead.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geographic region</title>
          <description>Geographic region (core versus non-core) was stratification factor for randomization. Core region comprises North America, Northern/Western Europe, and Australia. Non-core region comprises South America, Eastern Europe, and Asia-Pacific.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>core</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-core</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NSCLC Classification</title>
          <description>Histology (squamous versus non-squamous) was a stratification factor for randomization.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma NSCLC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="271"/>
                    <measurement group_id="B3" value="534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchoalveolar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Microcellulare carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Small cell lung cancer carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undifferentiated carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poorly differentiated non-small cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuro-Endocrine carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low differentiated carcinoma (neuro-endocrine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or unspecified histology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at Study Entry</title>
          <description>Stage IIIB (according to American Joint Committee on Cancer): primary tumor any stage, regional lymph node stage N3, no distant metastasis OR primary tumor stage T4, regional lymph node any stage, no distant metastasis. Stage IV: primary tumor any stage, regional lymph node any stage, distant metastasis present.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage III B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="420"/>
                    <measurement group_id="B2" value="415"/>
                    <measurement group_id="B3" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo</title>
        <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment.</description>
        <time_frame>Outcome measure was assessed every 3 weeks starting from randomization, during treatment period and every 3 months during follow-up period until death was recorded or up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
        <population>Evaluations of OS based on the ITT population. Subjects alive at the time of analysis were censored at their last date of follow-up (last visit or contact or at the data cut-off date). In the case of an incomplete date, if the day is missing, day 15 (the middle of the month) will be used.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo</title>
          <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment.</description>
          <population>Evaluations of OS based on the ITT population. Subjects alive at the time of analysis were censored at their last date of follow-up (last visit or contact or at the data cut-off date). In the case of an incomplete date, if the day is missing, day 15 (the middle of the month) will be used.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324" lower_limit="277" upper_limit="423"/>
                    <measurement group_id="O2" value="322" lower_limit="293" upper_limit="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size based on primary efficacy endpoint of OS. Clinically meaningful improvement defined as 30% improvement in median OS (i.e. HR of 0.76923, Sorafenib+C/P over Placebo+C/P -Null: theta&gt;=1, Alternative: theta&lt;=0.76923). With overall one-sided alpha of 0.025, 90% power and randomization of 1:1, one formal interim analysis and one final analysis were planned using O'Brien-Fleming type error spending function, and a total of 614 events (deaths) were required.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <p_value_desc>According to protocol specified O'Brien-Fleming type alpha spending function and 384 deaths at interim analysis (IA), one-sided alpha value for IA was 0.0046.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>Two treatment groups compared using one-sided log-rank test (Sorafenib+C/P over Placebo+C/P) with overall alpha of 0.025 stratified by same stratification factors as randomization</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS determined as time (days) from the date of randomization at start of study to disease progression (radiological or clinical) or death due to any cause, if death occurs before progression.</description>
        <time_frame>Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
        <population>PFS (based on the ITT population) for subjects without disease progression/death at the time of analysis were censored at the last evaluation date. PFS for surviving subjects without post-baseline tumor assessments were censored at one day. In the case of an incomplete date (missing day), day 15 (the middle of the month) will be used.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS determined as time (days) from the date of randomization at start of study to disease progression (radiological or clinical) or death due to any cause, if death occurs before progression.</description>
          <population>PFS (based on the ITT population) for subjects without disease progression/death at the time of analysis were censored at the last evaluation date. PFS for surviving subjects without post-baseline tumor assessments were censored at one day. In the case of an incomplete date (missing day), day 15 (the middle of the month) will be used.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" lower_limit="132" upper_limit="160"/>
                    <measurement group_id="O2" value="163" lower_limit="134" upper_limit="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two treatment groups compared using one-sided log-rank test (Sorafenib+C/P over Placebo+C/P) with alpha of 0.025 stratified by same stratification factors at randomization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.433</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Best Response</title>
        <description>Best overall tumor response for the ITT population was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased).</description>
        <time_frame>Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
        <population>Evaluations of overall best response rate based on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Best Response</title>
          <description>Best overall tumor response for the ITT population was determined according to Response Evaluation Criteria in Solid Tumors (RECIST). Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased).</description>
          <population>Evaluations of overall best response rate based on the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4"/>
                    <measurement group_id="O2" value="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8"/>
                    <measurement group_id="O2" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Objective response rate (ie. CR+PR rate) was compared between treatment arms using Cochran-Mantel-Haenszel test with one-side alpha 0.025 adjusting for same stratification factors as randomization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1015</p_value>
            <p_value_desc>no adjustments</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>difference in response rate (CR+PR rate)</param_type>
            <param_value>-3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.18</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>difference in response rates (Complete Response (CR) + Partial Response (PR)) = Placebo+C/P - Sorafenib+C/P</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response (PR or better) is defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented).</description>
        <time_frame>Tumor measurements and assessments based on RECIST criteria were performed every 6 weeks for the first 18 weeks of therapy ( week 6, 12, and 18) and every 12 weeks thereafter up to data cutoff (1Oct2007) used for planned formal interim analysis</time_frame>
        <population>Evaluations of duration of response based on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response (PR or better) is defined as the time from the first documented objective response of PR or CR, whichever is noted earlier, to disease progression or death (if death occurs before progression is documented).</description>
          <population>Evaluations of duration of response based on the ITT population.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="142" upper_limit="184"/>
                    <measurement group_id="O2" value="134" lower_limit="126" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome as Assessed by FACT-L Score. Change From Baseline in Total FACT-L at Cycles 3,5,7,9 and End of Treatment (EOT)</title>
        <description>Functional Assessment of Cancer Therapy - Lung cancer subscore (FACT-L). Patient reported outcome as assessed by FACT-L score. FACT-L questionnaire comprises statements about physical, social / family, emotional and functional well-being as well as additional concerns which have to be rated by the patients (0=&quot;not at all&quot; to 4=&quot;very much&quot;). Cycle duration defined as 21 days. Change from baseline in Total FACT-L on day 1 of cycles 3,5,7,9 (weeks 7,13,19 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.</description>
        <time_frame>Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every other cycle (i.e. Cycle 3, 5, 7 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis</time_frame>
        <population>Evaluations of Total FACT-L based on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome as Assessed by FACT-L Score. Change From Baseline in Total FACT-L at Cycles 3,5,7,9 and End of Treatment (EOT)</title>
          <description>Functional Assessment of Cancer Therapy - Lung cancer subscore (FACT-L). Patient reported outcome as assessed by FACT-L score. FACT-L questionnaire comprises statements about physical, social / family, emotional and functional well-being as well as additional concerns which have to be rated by the patients (0=&quot;not at all&quot; to 4=&quot;very much&quot;). Cycle duration defined as 21 days. Change from baseline in Total FACT-L on day 1 of cycles 3,5,7,9 (weeks 7,13,19 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.</description>
          <population>Evaluations of Total FACT-L based on the ITT population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="8.0"/>
                    <measurement group_id="O2" value="0.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="10.5"/>
                    <measurement group_id="O2" value="-1.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="8.1"/>
                    <measurement group_id="O2" value="-0.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="8.0"/>
                    <measurement group_id="O2" value="-0.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (EOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="10.6"/>
                    <measurement group_id="O2" value="-2.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Reported Outcome as Assessed by LCS Subscale Score. Change From Baseline in LCS Subscale at Cycles 2 Through 9 and at End of Treatment (EOT)</title>
        <description>Lung Cancer Symptoms (LCS) subscale ranges from 0 (severe debilitation) to 28 (asymptomatic). Cycle duration defined as 21 days. Change from baseline in LCS Subscale on day 1 of cycles 2 through 9 (weeks 4,7,10,13,16,19,22 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.</description>
        <time_frame>Outcome measure was assessed on Day 1 of Cycle 1 and Day 1 of every cycle (i.e. Cycle 2, 3, 4, 5 etc.) during treatment and at end of treatment visit or up to data cutoff (10ct2007) used for planned formal interim analysis</time_frame>
        <population>Evaluations of LCS Subscale based on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + C/P</title>
            <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcome as Assessed by LCS Subscale Score. Change From Baseline in LCS Subscale at Cycles 2 Through 9 and at End of Treatment (EOT)</title>
          <description>Lung Cancer Symptoms (LCS) subscale ranges from 0 (severe debilitation) to 28 (asymptomatic). Cycle duration defined as 21 days. Change from baseline in LCS Subscale on day 1 of cycles 2 through 9 (weeks 4,7,10,13,16,19,22 and 25) and end of treatment (EOT); cycle 1, day 1 used as baseline. EOT is determined by patient's last visit after treatment discontinuation.</description>
          <population>Evaluations of LCS Subscale based on the ITT population.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.7"/>
                    <measurement group_id="O2" value="-0.1" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.9"/>
                    <measurement group_id="O2" value="-0.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.9"/>
                    <measurement group_id="O2" value="-0.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.9"/>
                    <measurement group_id="O2" value="-0.5" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.9"/>
                    <measurement group_id="O2" value="-0.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.1"/>
                    <measurement group_id="O2" value="-0.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="3.2"/>
                    <measurement group_id="O2" value="-0.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.1"/>
                    <measurement group_id="O2" value="-0.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment (EOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.2"/>
                    <measurement group_id="O2" value="-0.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data were collected from the first subject's first visit (13 Feb 2006) to the planned formal interim analysis (01 Oct 2007 data cut-off date), and additional safety data were collected until the last subject's last visit (05 Feb 2009).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib + C/P</title>
          <description>Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + C/P</title>
          <description>Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="272" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="195" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Bone marrow cellularity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hemorrhage, GI, esophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hemorrhage, Gu, bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmia, atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Conduction abnormality, asystole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, supravent extrasystoles (pac;premnodal/junct contr)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>vasovagal episode</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia, ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia, ventricular arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia, ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia, atrial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>cardiac general - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Necrosis, GI, anus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Perforation, GI, colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fistula, GI, abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>perforation, GI, stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term, death NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term, sudden death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms - other</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, chest wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, joint</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Syndromes - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hepatobilary - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically), abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), blood</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), bladder (urinary)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), pleura (empyema)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), urinary tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, blood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, pleura (empyema)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically), mucosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, anal/perianal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, pleura (empyema)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC, urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, muscle (infection myositis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intraop injury, bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>GGT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Muscuskeletal - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Muscle weakness, extremity-lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Muscle weakness, whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>CNS ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mood alteration, euphoria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mood alteration, depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neurology - other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fistula, pulmonary, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fistula, pulmonary, lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Airway obstruction, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pulmonary - other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intraop injury, lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GI, abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, lower GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, upper GI, NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, bronchopulmonary NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, lung</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemorrhage pulmonary, respiratory tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism (vascular access)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vascular - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI CTC v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="454" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="450" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mucositis (functional/symptomatic), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, chest/thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, head/headache</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, joint</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, muscle</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, bone</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Pain, throat / pharynx / larynx</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Pain, tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="NCI CTC v3.0">Muscle weakness, whole body / generalized</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mood alteration, anxiety</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Mood alteration, depression</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title>Voice changes</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="NCI CTC v3.0">Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="459"/>
              </event>
              <event>
                <sub_title vocab="NCI CTC v3.0">Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="NCI CTC v3.0">Hemorrhage pulmonary, nose</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="463"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early. The planned biomarker analysis was suspended due to early termination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

